Switch to Rilpivirine/Emtricitabine/Tenofovir Single-Tablet Regimen of Human Immunodeficiency Virus-1 RNA-Suppressed Patients, Agence Nationale de Recherches sur le SIDA et les Hépatites Virales CO3 Aquitaine Cohort, 2012–2014

Abstract

We evaluated the efficacy and tolerability of a single-tablet regimen strategy in 304 HIV-1 virologically suppressed patients switching to RPV/FTC/TDF for adverse events or treatment simplification. This strategy maintained virologic suppression and was associated with improved tolerability after 12 months follow-up.

Switching to a rilpivirine/emtricitabine/tenofovir single-tablet regimen in RNA-suppressed patients infected with human immunodeficiency virus 1: Effectiveness, safety and costs at 96 weeks

“…The most frequent adverse event leading to discontinuation was renal impairment (5.5%), followed by gastrointestinal intolerance (4.8%). These findings differ from those published by other authors, who found that the most frequent adverse events were neurological disorders and gastrointestinal toxicity …”

“…The main reason for switching to RPV/FTC/TDF was simplification of ART and cost reductions (53.4% of patients). This result is consistent with other studies (49.2%‐73.7%). In all cases, these reasons were followed by occurrence of adverse events with the previous ART regimen, as it was also observed in this study.…”

“…This study evaluated the effectiveness and safety of an STR strategy in 146 virologically suppressed HIV‐1‐infected patients switching to RPV/FTC/TDF. Patients were followed up for 96 weeks after switch, which is longer than previously reported . The main finding of this study was that if all reasons for discontinuation of RPV/FTC/TDF were considered as failure to maintain virological suppression, the number of patients remaining virologically suppressed with RPV/FTC/TDF at week 96 was significantly lower than those reported at weeks 24 and 48 by other authors.…”

“…As for the safety profile of RPV/FTC/TDF, 14.4% of patients discontinued treatment owing to adverse events at week 96, which is almost three times higher than results reported elsewhere at week 24‐48 (3.1%‐6.2%); once again, this can be attributed to the longer follow‐up and the availability of new better tolerated treatment options.…”

“…Only two patients with VF (20.0%) developed drug resistance, and both showed good adherence in dispensing data records (99% and 100%). The percentages of VF and drug resistance reported elsewhere vary widely: 33.3%‐100% at week 24, 20.0%‐50.0% at week 48, and 66.7% after a median follow‐up of 31.7 weeks . In an observational study of patients who initiated RPV/FTC/TDF focusing on NNRTI resistance genotypes at baseline, Amiel et al .…”